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The identification and characterisation of Cryptosporidium genotypes and subtypes are fundamental to the 
study of cryptosporidiosis epidemiology, aiding in prevention and control strategies. The objective was to determine 
the genetic diversity of Cryptosporidium in samples obtained from hospitals of Rio de Janeiro, Brazil, and Buenos 
Aires, Argentina. Samples were analysed by microscopy and TaqMan polymerase chain reaction (PCR) assays for 
Cryptosporidium detection, genotyped by nested-PCR-restriction fragment length polymorphism (RFLP) analysis of 
the 18S rRNA gene and subtyped by DNA sequencing of the gp60 gene. Among the 89 samples from Rio de Janeiro, 
Cryptosporidium spp were detected in 26 by microscopy/TaqMan PCR. In samples from Buenos Aires, Cryptospo-
ridium was diagnosed in 15 patients of the 132 studied. The TaqMan PCR and the nested-PCR-RFLP detected Cryp-
tosporidium parvum, Cryptosporidium hominis, and co-infections of both species. In Brazilian samples, the sub-
types IbA10G2 and IIcA5G3 were observed. The subtypes found in Argentinean samples were IbA10G2, IaA10G1R4, 
IaA11G1R4, and IeA11G3T3, and mixed subtypes of Ia and IIa families were detected in the co-infections. C. hominis 
was the species more frequently detected, and subtype family Ib was reported in both countries. Subtype diversity 
was higher in Buenos Aires than in Rio de Janeiro and two new subtypes were described for the first time.
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Cryptosporidium infections in immunocompromised 
individuals can be asymptomatic or can have severe 
clinical symptoms, such as profuse diarrhoea, which is 
usually accompanied by weight loss, malabsorption syn-
drome, and cholangitis (Putignani & Menichella 2010). 
In the last two decades, some studies have described a 
significant risk factor for acquiring intestinal parasit-
ic infections among human immunodeficiency virus 
(HIV)-infected patients compared with non-HIV con-
trols. Cryptosporidiosis has a high prevalence among 
intestinal protozoa (Moura et al. 1989, Mohammad et al. 
2004, Akinbo et al. 2010).
Laboratory diagnosis of cryptosporidiosis is usually 
performed by identification of oocysts in stools using 
an acid-fast stain, but this does not allow species iden-
tification, as they are morphologically indistinguishable 
(Chalmers & Katzer 2013). The identification and char-
acterisation of Cryptosporidium species and population 
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variants (genotypes and subtypes) are fundamental to 
the study of cryptosporidiosis epidemiology and are 
useful in prevention and control strategies (Putignani 
& Menichella 2010). Because the oocysts of many spe-
cies are indistinguishable from one another, molecular 
methods are essential for identification of the species, 
genotype, and subtype of Cryptosporidium in order to 
specifically identify the organism responsible for the in-
fection and the source and routes of transmission. The 
taxonomy of Cryptosporidium has been standardised 
with a guideline that includes morphometric data on oo-
cysts, genetic characterisation, natural, and when feasi-
ble, experimental host specificity, and compliance with 
International Commission on Zoological Nomenclature 
rules (Ryan et al. 2014).
The methods currently used for detection and species 
characterisation of Cryptosporidium are based on nest-
ed-polymerase chain reaction (PCR), PCR-restriction 
fragment length polymorphism (RFLP), and real-time 
PCR (Xiao 2010). The genetic markers used are the gene 
encoding for 18S ribosomal subunit, the COWP gene, 
encoding a protein of the oocyst wall, the hsp70 gene, 
which encodes a heat shock protein, internal transcribed 
spacer (ITS)-1 and ITS-2, the TRAP gene, and the gene 
encoding the glycoproteins GP60 and GP40 (Xiao 2010, 
Navarro-i-Martinez et al. 2011, Galván et al. 2014). There 
is no standard genetic locus recommended for species 
identity, but RFLP or sequencing of the 18S rRNA gene 
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provides information about more species than the COWP 
gene locus (Muthusamy et al. 2006). Recent work has con-
firmed the utility of gp60 sequencing and mini and micro-
satellite markers in the study of the population structure 
of Cryptosporidium and in understanding the transmis-
sion dynamics of infection (Feng et al. 2014). Currently, 
nearly 20 Cryptosporidium species and genotypes have 
been reported in humans, including Cryptosporidium 
hominis, Cryptosporidium parvum, Cryptosporidium me-
leagridis, Cryptosporidium felis, Cryptosporidium canis, 
Cryptosporidium cuniculus, Cryptosporidium ubiqui-
tum, Cryptosporidium viatorum, Cryptosporidium muris, 
Cryptosporidium suis, Cryptosporidium fayeri, Crypto-
sporidium andersoni, Cryptosporidium bovis, Crypto-
sporidium scrofarum, Cryptosporidium tyzzeri, Cryp-
tosporidium erinacei and Cryptosporidium I genotypes 
from horse, skunk, and chipmunk (Xiao 2010, Liu et al. 
2014, Ryan & Hijjawi 2015).
In Brazil and Argentina, the prevalence of human 
cryptosporidiosis varies widely range between 7-24% 
(Velásquez et al. 1997, Bachur et al. 2008, Barboni et al. 
2008, Cardoso et al. 2011, Assis et al. 2013). However, 
there are few molecular studies of Cryptosporidium spe-
cies and genotypes in humans in these countries where 
reports about subtypes of Cryptosporidium are not de-
scribed (Carnevale et al. 2010, Meireles 2010, Velásquez 
et al. 2010, Rolando et al. 2012). Therefore, in the present 
study, we detected and characterised Cryptosporidium 
species and identified subtypes for the first time in fae-
cal and/or biopsy samples from HIV+ individuals (adults 
and children) seeking medical attention in public hospi-
tals in the cities of Rio de Janeiro, Brazil, and Buenos 
Aires, Argentina.
SUBJECTS, MATERIALS AND METHODS
Sample collection and DNA extraction in Rio de Ja-
neiro - Ages of the included patients ranged from 20-
75 years for adults and one-16 years for children, with 
a male/female ratio of 59/30. Eighty-nine faecal sam-
ples from HIV-infected patients with diarrhoea (82 
adults and 7 children of both sexes) were screened for 
intesti nal parasite infections, with special attention to 
Cryptosporidium spp, using a centrifuge-sedimenta-
tion technique, with two centrifugations of 2,000 g/2 
min (Ritchie 1948). The 89 stool samples were collected 
from 2009-2013 in three different public hospitals in Rio 
de Janeiro, originating from Antônio Pedro University 
Hospital [Faculty of Medicine, Fluminense Federal Uni-
versity (UFF)] (n = 77), Jesus Municipal Hospital (n = 
7), and Evandro Chagas Institute of Clinical Research 
(Oswaldo Cruz Foundation) (n = 5). Only samples with 
a medical request for the detection of Cryptosporidium 
spp were included in this study.
For Cryptosporidium oocyst identification, stool 
samples were subjected to a modified acid-fast staining 
technique (Ma & Soave 1983). After parasitological ex-
ams, all samples were stored at -20ºC until molecular 
characterisation. This study was conducted with the ap-
proval of the Ethical Review Committee for Research of 
the Faculty of Medicine, UFF, protocol 020/07.
Total genomic DNA was extracted from 300 mL of 
stool samples using FastDNA® kit (MP Biomedicals) ac-
cording to the manufacturer’s protocol. Samples were 
disrupted in an FP120 cell disruptor (MP Biomedicals) 
at a speed of 5.5 m/s for 10 s. Potential inhibitors were 
removed by further purification using QIAquick PCR 
purification kit (Qiagen), following the manufacturer’s 
instructions, and DNA extracts were stored at -20ºC un-
til further processing.
Sample collection and DNA extraction in Buenos Aires 
- The study population consisted of 132 adult patients of 
both sexes (113 male/19 female) diagnosed with HIV who 
attended the Francisco J Muñiz and José María Penna Hos-
pitals complaining of diarrhoea. Serial stool samples from 
each patient were processed for parasite analysis by exam-
ination of wet mount and slides stained using the modified 
Ziehl-Neelsen technique for cryptosporidia (Henriksen & 
Pohlenz 1981), and Weber trichrome (Weber et al. 1992) 
and Gram-chromothrope (Moura et al. 1996), for micro-
sporidia spores. DNA purification from stool samples was 
carried out by phenol-chloroform extraction according to 
Velásquez et al. (2010). Briefly, 1 mL of each sample was 
treated with 200 mL of ether and centrifuged for 5 min 
at 15,000 g. The pellet was re-suspended in 1 mL of 70% 
ethanol and stored overnight at -20ºC. Then, the sample 
was centrifuged for 3 min at 15,000 g, washed twice with 
1 mL of bidistilled water by centrifugation for 3 min at 
15,000 g, and dried at 37ºC. The pellet was incubated for 
45 min at 4ºC in 1 mL of sodium hypochlorite (33 g/L). 
After this step, the material was centrifuged and washed 
as previously described. The pellet was then re-suspended 
in 200 µL of phosphate-buffered saline pH 8 with 20 µL 
of 5% trypsin and incubated overnight at 37ºC at 200 rpm. 
All of the following steps were performed as previously 
described (Velásquez et al. 2010). Biopsy samples from 
the duodenum were collected by upper gastrointestinal 
endoscopy, fixed in formaldehyde, paraffin-embedded 
and stained with Giemsa and haematoxylin-eosin (Carey 
et al. 2004). Another biopsy specimen was collected in 
saline solution, stored at -20ºC and employed for DNA 
extraction and purification according to Velásquez et 
al. (2010). The research protocol was approved by the 
Ethical Committee for Research, Hospital Francisco J 
Muñiz, protocol 274.
The DNA recovery was above 10 pg, measured in a 
Qubit® fluorometer (Invitrogen, USA).
TaqMan PCR assays - The TaqMan PCR procedure 
combined a duplex reaction for the detec tion of Cryp- 
tosporidium species and C. parvum and a simple reaction 
for the detection of C. hominis, as described previously 
(Jothikumar et al. 2008). The assays were performed 
with a 7500 Real-Time PCR System (Life Technologies, 
USA). Each 20-μL duplex reaction (to identify Crypto-
sporidium species and C. parvum) contained 10 μL of 
2X Platinum Quantitative PCR SuperMix-UDG (Invit-
rogen), 100 nM of each probe (JVAP 18S and JVAGP2), 
250 nM of each primer (JVAF, JVAR, JVAGF, and JVA-
GR), and 5 μL of DNA. For the C. hominis assay, each 
20-μL reaction contained 10 μL of 2X Platinum Quan-
titative PCR SuperMix-UDG (Invitrogen), 250 nM of 
each primer (JVAF, JVAR, JVAGF, and JVAGR), 5 mM 
32 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 111(1), January 2016
MgCl
2
, twice the probe concentration used for the duplex 
assay (200 nM), and 5 μL of DNA. The Cryptosporidium 
PCR cycling conditions consisted of denaturation at 95ºC 
for 2 min followed by 45 cycles of denaturation at 94ºC for 
10 s, annealing at 55ºC for 30 s, and extension at 72ºC for 
20 s. All assays included positive controls (C. hominis and 
C. parvum) and negative controls (DNA extracted from 
faecal samples negative for any parasites). To investigate 
the presence of inhibitory substances, negative samples 
were contaminated with around 10 fg of Cryptosporidium 
DNA and subsequently submitted to TaqMan PCR.
Genotyping analysis - Cryptosporidium species were 
determined by nested PCR amplifying a 214 bp fragment 
of the small-subunit 18S rRNA gene and RFLP analysis 
of the secondary PCR products, using the restriction 
enzymes TaqI (Fermentas, Lifescience) and VspI (Fer-
mentas, Life Science). Primers and amplification condi-
tions used for PCR-RFLP were adopted from previous 
publications (Coupe et al. 2005). Reaction mixtures were 
prepared according to Velásquez et al. (2010), employing 
10X buffer containing (NH4)2SO4, and adding 400 ng/
µL of bovine serum albumin. Cycle conditions were as 
follows: one cycle of 94ºC for 5 min, 39 cycles of a dena-
turation step at 94ºC for 30 s, an annealing step at 60ºC 
(58ºC for the 2nd round) for 45 s, and an extension step at 
72ºC for 90 s, with a final extension for 10 min at 72ºC.
Enzymatic-digested products were fractionated on 
a 2% agarose gel and visualised by ethidium bromide 
staining. All diagnoses were confirmed by RFLP anal-
ysis of additional, independent PCR products from the 
same sample.
Samples that contained C. parvum and C. hominis 
were further subtyped by DNA sequencing of the gp60 
gene amplified by a nested PCR following the protocol 
described by Glaberman et al. (2002). Each sample was 
amplified at least three times by PCR. Primers AL3531 
and AL3533 were used in the primary PCR and prim-
ers AL3532 and LX0029 in the secondary PCR. gp60 
products were purified according to the manufactur-
er’s instructions using a NucleoSpin® Extract II kit 
(MACHEREY-NAGEL GmbH and Co KG, Germany). 
Sequencing was carried out in both directions by the 
sequencing services of Institute of Biophysics Carlos 
Chagas, Macromolecular Metabolism Laboratory, Fed-
eral University of Rio de Janeiro (UFRJ), and Medical 
Biochemistry Institute, SONDA Laboratory, UFRJ, for 
the Brazilian samples, and by Macrogen Service, for the 
Argentinean ones. The nucleotide sequences obtained 
in this study were aligned with reference sequences re-
trieved from GenBank and gp60 sequences. The result-
ing sequences were edited and aligned with the Bioedit 
Sequence Alignment Editor 7.0.5.3.
RESULTS
Samples from Brazil - Thirty faecal samples were par-
asitologically positive in the exams and Cryptosporidium 
sp. oocysts were observed in 17 (19.1%) samples. The oth-
er parasites detected in these samples were Strongyloides 
stercoralis (2.2%), Giardia duodenalis (2.2%), Entamoe-
ba coli (1.1%), Entamoeba histolytica/Entamoeba dispar 
complex (2.2%), Blastocystis sp. (5.6%), and Cystoisos-
pora belli (1.1%). The results of the dual TaqMan PCR 
procedure for the stool samples from patients are shown 
in Table I. The 18S rRNA TaqMan assay detected Cryp-
tosporidium in 23 (25.8%) samples. Four samples were 
amplified in the C. parvum assay, 14 samples were am-
plified as C. hominis, one sample was a mixed infection 
with C. hominis and C. parvum, and four samples were 
amplified only as a Cryptosporidium spp. Three samples 
previously determined to be Cryptosporidium-positive 
for microscopy were Cryptosporidium-negative using 
the TaqMan assay. For PCR inhibition control, these 
samples were contaminated with a known concentration 
of Cryptosporidium DNA and retested by PCR. All spik-
ing samples tested had DNA amplification showing no 
inhibition effect. Species and subtypes of all 26 samples 
considered Cryptosporidium-positive by TaqMan assay 
and/or microscopy were analysed by nested-PCR-RFLP 
for 18S rRNA and nested-PCR for gp60 (Table I). Eight 
of these samples did not amplify during 18S rRNA PCR 
or gp60 PCR and two amplified only in gp60 PCR. Nine 
samples were negative in microscopy and four amplified 
only for Cryptosporidium spp in the TaqMan PCR assay. 
The RFLP confirmed the result from the TaqMan assay, 
including the result with a mixed infection. The subtype 
IbA10G2 was observed in 13 C. hominis samples and 
was the only subtype found in this studied population. In 
four samples presented C. parvum, one was sequenced in 
which the subtype IIcA5G3 was found. The presence of 
C. parvum was observed only in the children group (4/7).
Samples from Argentina - The ages of 132 patients 
who participated in this study ranged from 20-50 years. 
Faecal and/or biopsy samples from 31 patients were posi-
tive for parasites and 14 for microsporidia. Cryptospo-
ridium was diagnosed in 15 patients (11.4%). The other 
parasites detected were C. belli (9.8%), G. duodenalis 
(5.3%), S. stercoralis (3%), and Cyclospora cayetanen-
sis (0.8%). Those 15 Cryptosporidium-positive samples 
were analysed by real-time PCR assays and the results 
are shown in Table II. Five samples were amplified in 
the C. parvum assay, nine samples were amplified for C. 
hominis, and one sample was co-infected with C. homi-
nis and C. parvum. Species of the 15 Cryptosporidium-
positive samples were analysed by nested-PCR-RFLP 
for 18S rRNA, revealing nine C. hominis infections, four 
C. parvum infections, and two co-infections of both spe-
cies. The results confirmed the species determined by 
real-time PCR, with the exception of another case of co-
infection that had been detected as C. parvum only. The 
subtypes were analysed by amplification and sequencing 
of the gp60 gene in eight samples obtained from biopsy. 
The subtypes for C. hominis were IbA10G2 in three 
samples and IaA10G1R4, IaA11G1R4, and IeA11G3T3 
in one sample each. In two samples with co-infections, 
mixed subtypes of Ia and IIa were detected.
DISCUSSION
In the present study, the diversity of Cryptosporidium 
parasites from patients living in the cities of Buenos Ai-
res and Rio de Janeiro was examined. Data on specific 
genotypes involved in human infections in the region are 
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still limited, and to the best of our knowledge, this is the 
first report on the study of the Cryptosporidium subtypes 
infecting humans performed in Argentina and Brazil.
The results showed that C. hominis was detected more 
frequently than C. parvum in HIV-infected patients from 
both areas, but co-infections of both species were also 
present. C. parvum and C. hominis have been reported as 
the most common species causing infections in HIV-in-
fected people in developed countries [France, Switzer-
land, Spain, and the United States of America (USA)] and 
developing countries (Jamaica, Kenya, Malaysia, Peru, 
Portugal, South Africa, South India, Thailand, and Viet-
nam) (Gatei et al. 2003, Zaidah et al. 2008). The results 
of the present work appear to be consistent with those 
in Peru, Australia, Kenya, South Africa, Thailand, the 
USA, and Vietnam, where C. hominis is reported to be 
the more common causative agent of cryptosporidiosis in 
immunocompromised people (Cama et al. 2007, Widmer 
& Sullivan 2012). Cryptosporidium subtyping at the gp60 
level in HIV infected patients has been carried out in a 
few countries (Xiao & Feng 2008).
Different types of molecular techniques have been 
used in the differentiation of Cryptosporidium species/
genotypes, with the SSU rRNA-based tools being the 
most employed, especially PCR-RFLP (Xiao 2010). 
The use of this gene is mainly due to the presence of 
semi-conserved and hyper-variable regions in a mul-
ti-copy. In our study, we applied this technique for spe-
cies identification, and it was also useful for co-infection 
detection. All positive samples by microscopy were ana-
lysed by a previously described TaqMan PCR assay that 
allowed differentiation of C. hominis and C. parvum at 
the species level. According to our results, both methods 
could be employed simultaneously to improve and con-
firm the results. Molecular methods for detecting Cryp-
tosporidium in clinical specimens have been shown to be 
more sensitive than conventional microscopy (Chalmers 
& Katzer 2013, Yang et al. 2013). The TaqMan procedure 
had a specificity of 94% for detecting Cryptosporidium 
in clinical specimens and a sensitivity that is better than 
conventional microscopy and comparable to other mo-
lecular methods used for confirmatory identification of 
Cryptosporidium species (Jothikumar et al. 2008).
Of four samples that amplified only as a Crypto-
sporidium spp in TaqMan PCR, one also amplified 
in nested-PCR gp60 and the subtype was defined as 
TABLE I
Results of microscopic examination, TaqMan polymerase chain reaction (PCR), PCR-restriction fragment  
length polymorphism (RFLP) 18S rDNA, and by gp60 PCR/sequencing of faecal samples  
from hospitals of the city of Rio de Janeiro, Brazil, for Cryptosporidium characterisation
Sample Microscopy Real-time PCR 18S rDNA/RFLP gp60/sequencing
Pc1 Cryptosporidium spp C. hominis C. hominis IbA10G2
Pc2 Cryptosporidium spp C. hominis C. hominis IbA10G2
Pc6 Negative C. hominis No amplification No amplification
Pc7 Negative C. hominis C. hominis IbA10G2
Pc8 Negative Cryptosporidium spp No amplification No amplification
Pc13 Negative Cryptosporidium spp No amplification No amplification
Pc16 Cryptosporidium spp Cryptosporidium spp No amplification No amplification
Pc17 Cryptosporidium spp No amplification No amplification No amplification
Pc20 Cryptosporidium spp Cryptosporidium spp C. hominis IbA10G2
Pc27 Negative C. hominis C. hominis IbA10G2
Pc28 Negative C. parvum No amplification No amplification
Pc44 Cryptosporidium spp No amplification No amplification No amplification
Pc46 Cryptosporidium spp No amplification No amplification No amplification
Pc52 Negative C. hominis C. hominis IbA10G2
Pc78 Cryptosporidium spp C. hominis C. hominis IbA10G2
Pc79 Cryptosporidium spp C. hominis C. hominis IbA10G2
Pc80 Cryptosporidium spp C. hominis C. hominis Cryptosporidium
Pc81 Cryptosporidium spp C. hominis C. hominis IbA10G2
Pc82 Cryptosporidium spp C. hominis C. hominis IbA10G2
Pc83 Cryptosporidium spp C. hominis C. hominis IbA10G2
Pc84 Cryptosporidium spp C. hominis C. hominis IbA10G2
Pc85 Cryptosporidium spp C. hominis C. hominis Cryptosporidium
Pc86 Negative C. parvum No amplification IbA10G2
Pc87 Negative C. parvum No amplification Cryptosporidium
Pc88 Cryptosporidium spp C. parvum/C. hominis C. parvum/C. hominis Cryptosporidium
Pc89 Cryptosporidium spp C. parvum C. parvum IIcA5G3
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IbA10G2. The others three samples were probably differ-
ent species of Cryptosporidium and additional analysis is 
necessary for confirmation. We did not have success in 
amplifying the 18S and gp60 gene in these samples.
Given that C. hominis and C. parvum were respon-
sible for the Cryptosporidium infections in the HIV-in-
fected patients studied here, a further evaluation of the 
genetic variation within these two species was carried 
out by DNA sequence analysis of the 60-kDa glycopro-
tein gene. This single-copy gene has tandem repeats of 
the serine-coding trinucleotide TCA, TCG, or TCT at 
the 5’ end of the gene, which vary in number, and there 
are extensive sequence differences in the nonrepeat re-
gions, which categorise each species to several subtype 
families (Strong et al. 2000, Xiao 2010).
Until now, C. hominis had nine gp60 subtype fami-
lies, Ia-Ij (Nichols et al. 2014). The subtype family Ib is 
dominant and broadly distributed, with more than 70% 
of records referencing this subtype (Jex & Gasser 2010), 
followed by Ia, Id, and Ie, with less than 10% each. Ad-
ditionally, there is variation in subtype richness, diver-
sity, and distribution within each of the gp60 subtype 
families of C. hominis. The subtype family Ib is repre-
sented by nine subtypes, dominated by IbA10G2, which 
is distributed on all inhabited continents. This subtype 
has been implicated in some waterborne and foodborne 
outbreaks of human cryptosporidiosis (Sulaiman et al. 
2001, Glaberman et al. 2002, Cohen et al. 2006, Wider-
ström et al. 2014). Subtype IbA10G2 has been found in 
approximately 50% of C. hominis-associated outbreaks 
in the USA (Xiao & Ryan 2004). In a longitudinal study 
in Lima, Peru, IbA10G2 was more virulent than other C. 
hominis subtypes (Cama et al. 2008).
In samples from Rio de Janeiro, only one subtype of 
C. hominis was identified, corresponding to IbA10G2. 
Instead, in samples from Buenos Aires, three C. homi-
nis subtype families were detected (Ib, Ia, and Ie). The 
IbA10G2 was the predominant subtype, but three oth-
ers were identified, namely IaA10G1R4, IaA11G1, and 
IeA11G3T3. Although the sample size is small, homo-
geneity within the C. hominis at the gp60 locus is un-
usual, as subtype families such as Ia and Id are usually 
equally abundant in most developing countries (Leav et 
al. 2002, Peng et al. 2003, Cama et al. 2008, Valenzuela 
et al. 2014). It has been shown that there are differences 
in the molecular epidemiology of C. hominis between 
developing and developed countries. In nonindustrial-
ised countries, a greater variety of C. hominis subtypes 
have been reported with multiple subtype families and 
multiple subtypes within families Ia and Id. Much less 
genetic diversity is observed in C. hominis in some in-
dustrialised countries, where most C. hominis infections 
are caused by the Ib subtype family, with the majority 
of these cases having the IbA10G2 subtype (Xiao 2010). 
Recently, the subtype IbA10G2 was also prevalent in 161 
cryptosporidiosis cases in two hospitals in Barcelona, 
Spain, corresponding to 90% of all C. hominis isolates 
(Segura et al. 2015). The presence of Ib and IIc subtype 
families in Brazil may suggest anthroponotic transmis-
sion, while the findings from Argentina suggest that zo-
onotic transmission may play a role.
Among the Ia subfamily, IaA12G1R1 is the most 
common subtype and has been reported in humans from 
Japan, Nepal, Pakistan, and Peru (Wu et al. 2003, Cama 
et al. 2008, Chalmers 2008). Among this subfamily, two 
subtypes were identified in the Argentinean samples, 
belonging to IaA10G1R4 (GenBank KT381976) and 
IaA11G1R4 (GenBank KT381977), and both have not 
been previously described.
Subtype family Ie has low subtype richness and di-
versity, as most Ie human infections in developing coun-
tries are caused by IeA11G3T3 (Sharma et al. 2013, Ad-
amu et al. 2014, Valenzuela et al. 2014). Our study in 
Buenos Aires identified this subtype in one sample. 
Regarding C. parvum, gp60 subgenotyping for Bra-
zilian patients identified only the IIcA5G3 lineage in one 
sample. The subtype family IIa is globally distributed and 
the most common C. parvum infection in humans (Xiao 
& Feng 2008). The subtype families IIc and IId are also 
common and broadly distributed. The other known fami-
lies, IIb and IIe-k, are rare (Jex & Gasser 2010). Eibach et 
al. (2015) described that all identified C. parvum and C. 
hominis subtypes found in Brazilian human samples have 
not yet been identified in any animal samples, suggesting 
a dominant anthroponotic transmission in the region of 
Rio de Janeiro. These authors also found similar results 
in a rural region of Ghana. This type of transmission is 
expected in the urban region of Rio de Janeiro.
Genotyping by TaqMan PCR and 18S PCR-RFLP, 
and subtyping by gp60-based sequencing revealed mixed 
infections of Cryptosporidium species/subtypes in three 
samples. In one brazilian sample, C. hominis and C. par-
TABLE II
Molecular analyses of Cryptosporidium spp positive faecal 
and biopsy samples from the city of Buenos Aires, Argentina
Samples
Real-time  
PCR
18S rDNA/ 
RFLP
gp60/ 
sequencing
1 C. parvum C. parvum NP
2 C. parvum C. parvum NP
4 C. hominis C. hominis NP
6 C. hominis C. hominis IbA10G2
21 C. hominis C. hominis IbA10G2
22 C. hominis C. hominis IbA10G2
23 C. hominis C. hominis IaA10G1R4
24 C. hominis C. hominis IeA11G3T3
25 C. hominis C. hominis IaA11G1R4
27 C. hominis/ 
C. parvum
C. parvum/ 
C. hominis
Ia, IIa
28 C. parvum C. hominis/ 
C. parvum
Ia, IIa
39 C. parvum C. parvum NP
46 C. parvum C. parvum NP
47 C. hominis C. hominis NP
50 C. hominis C. hominis NP
NP: not performed; PCR: polymerase chain reaction; RFLP: 
restriction fragment length polymorphism.
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vum were detected for both genotyping assays, but the 
gp60 subtyping was not possible to analyse. For the Ar-
gentinean samples, co-infection of C. hominis and C. par-
vum were detected in two cases, with the subtype families 
Ia and IIa. There are few records showing mixed infec-
tions at the subtyping level (Ajjampur et al. 2010, Sharma 
et al. 2013), and this is the first report for human samples 
from Argentina. The interference of the subtypes in the 
severity of the infection also beginning to be studied and 
the IbA10G2 subtype has been described as one of the 
most virulent among the subtypes of C. hominis (Li et 
al. 2013). Subtype family IbA10G2 was reported in both 
countries, but great subtype diversity was detected in Ar-
gentina. So far, only two studies have reported subtyping 
of Cryptosporidium in South America, involving Peruvi-
an children (Cama et al. 2008) and Peruvian HIV-infected 
persons (Cama et al. 2007). Differentiating the species 
and subtypes requires the use of high resolution molecular 
tools, and subtyping is important for understanding popu-
lation structure. Further information from larger samples 
is necessary to provide insights on subtype lineages to 
elucidate the value of geographical/pathogenic variation 
in Cryptosporidium species/genotypes.
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